Protalix Biotherapeutics, Inc.
(NYSE Amex Equities : PLX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
CERNCerner Corporation
-0.24%67.857.6%$119.39m
DGXQuest Diagnostics Incorporated
-0.56%104.384.2%$99.32m
LHLaboratory Corporation of America Holdings
-0.29%172.302.3%$83.95m
SRCLStericycle, Inc.
-2.90%50.996.3%$47.20m
HMSYHMS Holdings Corp.
0.44%36.881.8%$18.69m
HCSGHealthcare Services Group, Inc.
0.27%25.706.7%$18.47m
OMCLOmnicell, Inc.
1.28%73.7210.4%$17.68m
MDRXAllscripts Healthcare Solutions, Inc.
0.58%10.4410.2%$14.91m
HSTMHealthStream, Inc.
-0.11%26.496.7%$5.46m
CPSIComputer Programs and Systems, Inc.
0.80%24.0032.3%$2.96m
BASIBioanalytical Systems, Inc.
-1.09%3.630.3%$0.28m
PMDPsychemedics Corporation
5.50%8.740.7%$0.20m
IDXGInterpace Diagnostics Group, Inc.
4.91%0.813.3%$0.09m
PLXProtalix Biotherapeutics, Inc.
-3.17%0.225.8%$0.05m
STRMStreamline Health Solutions, Inc.
-11.27%1.220.3%$0.03m

Company Profile

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.